Affiliation:
1. Department of Chemistry, Kyonggi University, Suwon 16227, Republic of Korea
2. College of Pharmacy, Keimyung University, Daegu 42691, Republic of Korea
Abstract
Src family kinases (SFKs) are non-receptor tyrosine kinases that are recognized as proto-oncogenic products. Among SFKs, YES1 is frequently amplified and overexpressed in a variety of human tumors, including lung, breast, ovarian, and skin cancers. YES1 plays a pivotal role in promoting cell proliferation, survival, and invasiveness during tumor development. Recent findings indicate that YES1 expression and activation are associated with resistance to chemotherapeutic drugs and tyrosine kinase inhibitors in human malignancies. YES1 undergoes post-translational modifications, such as lipidation and nitrosylation, which can modulate its catalytic activity, subcellular localization, and binding affinity for substrate proteins. Therefore, we investigated the diverse mechanisms governing YES1 activation and its impact on critical intracellular signal transduction pathways. We emphasized the function of YES1 as a potential mechanism contributing to the anticancer drug resistance emergence.
Funder
Kyonggi University’s Graduate Research Assistantship 2023, and a Basic Science Research Program grant
National Research Foundation (NRF) of the Republic of Korea
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference104 articles.
1. Understanding and targeting resistance mechanisms in cancer;Lei;MedComm,2023
2. Raji, L., Tetteh, A., and Amin, A. (2023). Role of c-Src in carcinogenesis and drug resistance. Cancers, 16.
3. Src family kinases, key regulators of signal transduction;Parsons;Oncogene,2004
4. Regulation of SRC family kinases in human cancers;Sen;J. Signal Transduct.,2011
5. A renaissance for YES in cancer;Lapouge;Oncogene,2023